Viscosupplementation (VS) and physical therapy are both used to treat pain associated with knee osteoarthritis (OA).
Evidence Acquisition:
PubMed and EMBASE searches were performed to July 2013. Search terms included hyaluronic acid OR hylan, physical therapy OR exercise, AND osteoarthritis.
Study Design:
Clinical review.
Level of Evidence:
Level 4.
Results:
The efficacy and safety of VS in painful knee OA is well documented, as are the appropriate candidates for this intervention. Studies suggest that adding VS to physical therapy and therapeutic exercise may lead to improved pain reduction and increased functionality compared with physical therapy alone.
Conclusion:
Appropriately selected patients undergoing physical therapy for knee OA may benefit from VS.
AltmanRDMoskowitzR. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol. 1998;25:2203-2212.
2.
AltmanRDRosenJEBlochDAHatoumHT. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage. 2011;19:1169-1175.
3.
AltmanRDRosenJEBlochDAHatoumHTKornerP. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial). Semin Arthritis Rheum. 2009;39:1-9.
4.
AntmanEMBennettJSDaughertyAFurbergCRobertsHTaubertKA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
5.
ArnoldWFullertonDSHolderSMayCS. Viscosupplementation: managed care issues for osteoarthritis of the knee. J Manag Care Pharm. 2007;13:3-19.
6.
AtamazFKirazliYAkkocY. A comparison of two different intra-articular hyaluronan drugs and physical therapy in the management of knee osteoarthritis. Rheumatol Int. 2006;26:873-878.
7.
BannuruRRNatovNSDasiURSchmidCHMcAlindonTE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis—meta-analysis. Osteoarthritis Cartilage. 2011;19:611-619.
8.
BellamyNCampbellJRobinsonVGeeTBourneRWellsG. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;(2):CD005321.
9.
BrandtKDBlockJAMichalskiJPMorelandLWCaldwellJRLavinPT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res. 2001;385:130-143.
10.
BraultMWHootmanJHelmickCGTheisKAArmourBS. Prevalence and most common causes of disability among adults—United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58:421-426.
11.
BrzusekDPetronD. Treating knee osteoarthritis with intra-articular hyaluronans. Curr Med Res Opin. 2008;24:3307-3322.
12.
CabornDRushJLanzerWParentiDMurrayC. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31:333-343.
13.
CarrabbaMPParesceEAngeliniMReKATorchianaEEMPerbelliniA. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm. 1995;15:25-31.
14.
Centers for Disease Control and Prevention. A National Public Health Agenda for Osteoarthritis. Atlanga, GA, Centers for Disease Control and Prevention; 2010.
ChevalierXJeroschJGoupilleP. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis. 2010;69:113-119.
18.
ColenSvan den BekeromMPMulierMHaverkampD. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. 2012;26:257-268.
19.
DayRBrooksPConaghanPGPetersenM. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol. 2004;31:775-782.
20.
DillonCFRaschEKGuQHirschR. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol. 2006;33:2271-2279.
21.
DixonASJacobyRKBerryHHamiltonEBD. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin. 1988;11:205-213.
22.
DougadosMNguyenMListratVAmorB. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage. 1993;1:97-103.
FrizzieroLPasquali-RonchettiI. Intra-articular treatment of osteoarthritis of the knee: an arthroscopic and clinical comparison between sodium hyaluronate (500-730 kDa) and methylprednisolone acetate. J Orthop Traumatol. 2002;3:89-96.
25.
GambaroGPerazellaMA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003;253:643-652.
GoldbergVMGoldbergL. Intra-articular hyaluronans: the treatment of knee pain in osteoarthritis. J Pain Res. 2010;3:51-56.
28.
GrecomoroGMartoranaUDi MarcoC. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica. 1987;5:137-141.
29.
HepperCTHalvorsonJJDuncanSTGregoryAJDunnWRSpindlerKP. The efficacy and duration of intra-articular corticosteroid injection for knee osteoarthritis: a systematic review of level I studies. J Am Acad Orthop Surg. 2009;17:638-646.
30.
HuangMHYangRCLeeCLChenTWWangMC. Preliminary results of integrated therapy for patients with knee osteoarthritis. Arthritis Rheum. 2005;53:812-820.
31.
HuskissonECDonnellyS. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxford). 1999;38:602-607.
JubbRWPivaSBeinatLDacreJGishenP. A one-year, randomised, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57:467-474.
35.
KarlssonJSjogrenLSLohmanderLS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology. 2002;41:1240-1248.
36.
KawasakiTKurosawaHIkedaH. Therapeutic home exercise versus intraarticular hyaluronate injection for osteoarthritis of the knee: 6-month prospective randomized open-labeled trial. J Orthop Sci. 2009;14:182-191.
37.
KeanWFRainsfordKDKeanIR. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology. 2008;16:53-75.
38.
KemperFGebhardtUMengTMurrayC. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21:1261-1269.
39.
LaineL. Gastrointestinal safety of coxibs and outcomes studies: what’s the verdict?J Pain Symptom Manage. 2002;23(suppl 4):S5-S10.
40.
LaineL. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage. 2003;25(suppl 2):S32-S40.
41.
LohmanderLSDalénNEnglundG. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis. 1996;55:424-431.
42.
LohmanderLSEnglundPMDahlLLRoosEM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35:1756-1769.
43.
McHughesMLipmanAG. Managing osteoarthritis pain when your patient fails simple analgesics and NSAIDs and is not a candidate for surgery. Curr Rheumatol Rep. 2006;8:22-29.
44.
NeustadtDH. Intra-articular injections for osteoarthritis of the knee. Cleve Clin J Med. 2006;73:897-898, 901-904, 906-911.
PuhlWBernauAGreilingH. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage. 1993;1:233-241.
47.
RaynauldJPGoldsmithCHBellamyN. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2005;13:111-119.
48.
RaynauldJPTorranceGWBandP. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10:506-517.
49.
RutjesAWJüniPda CostaBRTrelleSNüeschEReichenbachS. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;157:180-191.
50.
ScaleDWobigMWolpertW. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res. 1994;55:220-232.
51.
SchumacherHRChenLX. Injectable corticosteroids in treatment of arthritis of the knee. Am J Med. 2005;118:1208-1214.
52.
StitikTPBlacksinMFStiskalDM. Efficacy and safety of hyaluronan treatment in combination therapy with home exercise for knee osteoarthritis pain. Arch Phys Med Rehabil. 2007;88:135-141.
53.
StrandVBarafHSLavinPTLimSHosokawaH. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2012;20:350-356.
TamirERobinsonDKorenRAgarGHalperinN. Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol. 2001;19:265-270.
58.
TetikSOnesKTetikC. Efficacy of intra-articular hylan G-F 20 on osteoarthritis of the knee. Pain Clinic. 2003;15:459-466.
59.
TurajaneTAmphansapTLabpiboonpongVMaungsiriS. Total knee replacement following repeated cycles of intra-articular sodium hyaluronate (500-730 kDa) in failed conservative treatment of knee osteoarthritis: a 54-month follow-up. J Med Assoc Thai. 2009;92(suppl 6):S63-S68.
60.
van der LindenMWvan der BijSWelsingPKuipersEJHeringsRM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2009;68:668-673.
61.
WaddellDD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin. 2003;19:575-580.
62.
WaddellDDBrickerD. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg. 2006;19:19-27.
63.
WaddellDDBrickerDC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv. 2006;15:53-59.
64.
WaddellDDBrickerDC. Total knee replacement delayed with hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007;13:113-121.
65.
WhitmanCAllenDComadollJLThomasonHCOweidaSJ. A retrospective study of SUPARTZ and repeat treatment for osteoarthritis pain in the knee. J Manag Care Med. 2010;13:43-47.
66.
WobigMDickhutAMaierRVetterG. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20:410-423.
67.
WolfeMMLichtensteinDRSinghG. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.
68.
ZhaoSZReynoldsMWLejkowithJWheltonAArellanoFM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther. 2001;23:1478-1491.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
